Previously, other researchers have also reported that the combination of microtubule-targeting agents (e.g., paclitaxel and eribulin) and various PI3K/AKT/mTOR inhibitors suppressed the EMT pathway in ovarian cancer [10]. This evidence concerns the gene AKT1 and ovarian cancer.